Nuclear Medicine, Proton Therapy, Brachytherapy reports and directories

Nuclear medicine, proton therapy and brachytherapy are niche markets which together represents less than 0.1% of the global health expenditures but should grow three times faster. While the global expenses on health reached some US$ 7,500 billion in 2016 and should growth by 3-4% a year to 2030, the nuclear medicine, proton therapy and brachytherapy markets reached over US$ 6 billion in 2016 and are expected to growth more than 10% annually till 2030.

These exciting healthcare technologies are covered in several reports and directories with over 1,900 pages of unbiased and factual intelligence from experts, including comprehensive profiles of the hundreds of companies active in nuclear medicine, cyclotrons, proton therapy and brachytherapy. Each report can be customized to specific geographic areas, indications or modalities upon request. Sample pages and complete table of contents are available upon request. MEDraysintell also welcomes your requests for specific intelligence needs in these areas.

The global radiopharmaceuticals market has entered an era of high potential for growth, involving new technologies and a high number of products close to being marketed or under advanced stage development. Radiotherapeutics are key drivers of this growth with several blockbuster radiotherapeutics to be marketed in the coming years.

The proton therapy market has been very active during the last two years, with many treatment rooms ordered worldwide. There is now a clear positive stance on the future of the proton therapy market, and this technology is becoming a real part of the global radiotherapy world.

The global market for brachytherapy is expected to grow by 8% a year to 2030 mainly driven by the microspheres and electronic brachytherapy and with the LDR brachytherapy seeds market mainly growing in emerging regions.

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.
We offer the most comprehensive set of reports and directories, with over 1,900 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

Paul-Emmanuel Goethals, MBA
Chemin du Cyclotron, 6
1348 Louvain-la-Neuve, Belgium
peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
rz@medraysintell.com
Mobile: +33 6 82 80 06 00

This release was published on openPR.